Adelaide Research & Scholarship: Search

Search

Results 1-10 of 10 (Search time: 0.002 seconds).

previous
1
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2013	STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent manner	Schafranek, L.; Nievergall, E.; Powell, J.; Hiwase, D.; White, D.; Hughes, T.; Leclercq, T.
	2010	Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial	Yeung, D.; Osborn, M.; White, D.; Branford, S.; Haswell, L.; Slader, C.; Issa, S.; Hiwase, D.; Hertzberg, M.; Schwarer, A.; Filshie, R.; Arthur, C.; Kwan, Y.; Forsyth, C.; Ross, D.; Mills, A.; Grigg, A.; Hughes, T.; Annual Meeting of the American Society of Hematology (52nd : 2010 : Orlando, Fl.)
	2016	TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy	Nievergall, E.; Reynolds, J.; Kok, C.; Watkins, D.; Biondo, M.; Busfield, S.; Vairo, G.; Fuller, K.; Erber, W.; Sadras, T.; Grose, R.; Yeung, D.; Lopez, A.; Hiwase, D.; Hughes, T.; White, D.
	2014	Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells	Nievergall, E.; Ramshaw, H.; Yong, A.; Biondo, M.; Busfield, S.; Vairo, G.; Lopez, A.; Hughes, T.; White, D.; Hiwase, D.
	2013	Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells	White, D.; Eadie, L.; Saunders, V.; Hiwase, D.; Hughes, T.
	2010	Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy	Hiwase, D.; White, D.; Zrim, S.; Saunders, V.; Vaz de Melo, J.; Hughes, T.
	2010	Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors	Hiwase, D.; White, D.; Powell, J.; Saunders, V.; Zrim, S.; Frede, A.; Guthridge, M.; Lopez, A.; D'Andrea, R.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.
	2008	Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications	Hiwase, D.; Saunders, V.; Hewett, D.; Frede, A.; Zrim, S.; Dang, P.; Eadie, L.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.; White, D.
	2013	Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cells	Hiwase, D.; Saunders, V.; Nievergall, E.; Ross, D.; White, D.; Hughes, T.
	2015	Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia	Schafranek, L.; Nievergall, E.; Powell, J.; Hiwase, D.; Leclercq, T.; Hughes, T.; White, D.